Categories
Change Password!
Reset Password!
Estimating changes
in serum calprotectin level might be helpful in predicting favorable treatment
response in active AS patients.
According to a study published in the Journal Modern Rheumatology, the serum calprotectin levels present as a promising biomarker to detect severity, risk, and treatment response of ankylosing spondylitis (AS).
The analysis involved 260 healthy controls (HCs) and 262 AS patients. The pharmaceutical therapy was given to 142 active AS patients and their clinical response was determined using ASAS 40 improvement criteria. The AS patients and HCs went through extraction of 4 mL blood sample during enrollment and 142 active AS patients at month 1, 3, 6 postoperatively. Enzyme-linked immune sorbent assay (ELISA) was used to assess serum calprotectin, IL-17, TNF-α, and IL-1β expressions.
AS patients
exhibited greater expression of calprotectin as compared to HCs. The baseline
calprotectin was noticed to be of great diagnostic value for AS as per Receiver
Operating Curve (ROC) analysis. The VAS, BASFI, BASDAI, ESR, CRP and PGA showed
a positive relationship with calprotectin level. The IL-17, TNF-α,
and IL-1β also showed elevated expressions with higher calprotectin
levels. Active AS patients showed significantly decreased calprotectin levels
from the baseline to 1, 3 or 6 months after the treatment. Moreover, patients
obtained ASAS 40 were the more significant calprotectin shift during the first
month, and this shift could estimate patients achieving ASAS 40 with AUC of
0.691.
Modern Rheumatology
Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment.
Hua Hu et al.
Comments (0)